综合分子对接和分子动力学揭示HER2 L755S,T798I和T798M的抑制剂,基于库尔库衍生物的大数据库
Mantiqa Syafa Duvadillan Gusrin1, Yonika Arum Larasati2, Rohmad Yudi Utomo3
1Graduate School of Master of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia.
这项研究使用虚拟查来发现针对特定HER2突变 (L755S,T798I,T798M) 的新黄素衍生物. 两个化合物CHEMBL3758656和CHEMBL3827366显示出作为乳腺癌治疗的HER2抑制剂的希望.
科学领域:
- 计算化学和药物发现.
- 瘤学和分子生物学.
背景情况:
- 由于突变,HER2阳性乳腺癌通常会对治疗产生耐药性.
- 针对L755S,T798I和T798M等特定的HER2突变是克服抗性的关键.
研究的目的:
- 为了确定具有对HER2突变 (L755S,T798I,T798M) 选择性结合亲和力的新型黄素衍生物.
- 评估这些衍生品作为针对HER2阳性乳腺癌的向治疗药物的潜力.
主要方法:
- 从ChEMBL数据库中使用KNIME和MOE软件对黄素衍生物进行虚拟选.
- 在HER2突变的in silico建模和分子对接和动态模拟.
- 用ADMET进行分析,以评估药理动力学和毒性特性.
主要成果:
- 从505.5的初始组中过了317种黄素衍生物.
- 确定了20种比拉帕提尼布更好的结合亲和力与野生型HER2的化合物.
- 选择了对HER2突变的最低对接分数的五种化合物,包括CHEMBL3758656和CHEMBL3827366.
- 确认了化合物的关键结合相互作用和有利的ADMET概况.
结论:
- 通过虚拟查,CHEMBL3758656和CHEMBL3827366被确定为强大的HER2抑制剂.
- 这些化合物对关键的HER2突变 (L755S,T798I,T798M) 具有很高的结合亲和力.
- 它们有利的ADMET特性表明,它们可能是治疗HER2阳性乳腺癌的替代疗法.
更多相关视频
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
06:03Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
相关概念视频
Kinetic Molecular Theory: Molecular Velocities, Temperature, and Kinetic Energy
Molecular Models
Molecular Orbital Theory II
Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
Molecular Orbital Theory I
Predicting Molecular Geometry
